I-Mab General and Administrative Expenses 2011-2026 | IMAB

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses I-Mab

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	-	900 M	402 M	655 M	66.4 M	25.4 M	-	-	-	-	-	-

All numbers in CNY currency

Indicator range from annual reports

Maximum	Minimum	Average
900 M	25.4 M	410 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Nymox Pharmaceutical Corporation NYMX	5.85 M	-	-19.68 %	$ 18.4 M	Canada
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Aptorum Group Limited APM	5.41 M	$ 0.9	-2.33 %	$ 6.62 M	China
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
ACADIA Pharmaceuticals ACAD	488 M	$ 21.96	-0.68 %	$ 3.64 B	USA
RedHill Biopharma Ltd. RDHL	32.4 M	$ 1.02	-0.49 %	$ 428 M	Israel
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Aligos Therapeutics ALGS	20.7 M	$ 6.4	4.4 %	$ 63.3 M	USA
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
Aptinyx APTX	19.8 M	-	-39.0 %	$ 4.57 M	USA
Aridis Pharmaceuticals ARDS	7.16 M	-	17.91 %	$ 11.1 M	USA
Avenue Therapeutics ATXI	3.65 M	-	-52.27 %	$ 4.45 M	USA
Amphastar Pharmaceuticals AMPH	85.9 M	$ 21.41	1.9 %	$ 1 B	USA
Aravive ARAV	13 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
BioDelivery Sciences International BDSI	106 M	-	-4.8 %	$ 255 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Brainstorm Cell Therapeutics BCLI	5.78 M	-	-2.5 %	$ 5.88 M	USA
Kazia Therapeutics Limited KZIA	4.51 M	$ 12.26	3.72 %	$ 1.62 B	Australia
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
BioNTech SE BNTX	286 M	$ 105.46	-0.09 %	$ 27.2 B	Germany
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	79.8 M	$ 4.08	0.25 %	$ 436 M	USA
Arcutis Biotherapeutics ARQT	275 M	$ 23.26	1.75 %	$ 2.96 B	USA
Cara Therapeutics CARA	8.74 M	-	-3.03 %	$ 260 M	USA
Autolus Therapeutics plc AUTL	132 M	$ 1.44	-5.88 %	$ 383 M	Britain
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
BioXcel Therapeutics BTAI	20.5 M	$ 1.06	-3.64 %	$ 12.9 M	USA
CASI Pharmaceuticals CASI	23.8 M	-	-	$ 35.4 M	USA
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Cabaletta Bio CABA	29.6 M	$ 2.95	-3.28 %	$ 296 M	USA
Can-Fite BioPharma Ltd. CANF	3.66 M	$ 2.91	-1.36 %	$ 4.79 M	Israel
bluebird bio BLUE	166 M	-	-	$ 546 M	USA
CymaBay Therapeutics CBAY	52 M	-	-	$ 3.45 B	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA